De Novo Classification Request for DigniCap Scalp Cooling System (DEN150010) (2015)

Government Record · U.S. Food and Drug Administration, Center for Devices and Radiological Health; requester Dignitana AB · March 6, 2015

U.S. Food et al., 2015-03-06: FDA de novo classification of the DigniCap scalp cooling system, creating regulation 21 CFR 878.4360 (product code PMC, class II). The indication is limited to reducing the likelihood of chemotherapy-induced alopecia in women with breast cancer.

The DigniCap™ Scalp Cooling System is indicated to reduce the likelihood of chemotherapy – induced alopecia in women with breast cancer.

p.1, INDICATIONS FOR USE

U.S. Food et al., 2015-03-06: FDA de novo classification of the DigniCap scalp cooling system, creating regulation 21 CFR 878.4360 (product code PMC, class II). The indication is limited to reducing the likelihood of chemotherapy-induced alopecia in women with breast cancer. This is a de novo grant, not a 510(k). The document cover prints 'DATE OF DE NOVO: MARCH 6, 2015'; the openFDA record for DEN150010 gives a decision date of 2015-12-08, when FDA announced the marketing authorisation, and that is the date used here. Labelling reproduced in the decision states that scalp cooling with taxanes plus anthracyclines 'has not been shown to be successful in preventing chemotherapeutic drug induced' alopecia. Prescription use only. The hyphen spacing in the quotation ('chemotherapy – induced') is the PDF's own line-break rendering, kept verbatim. No funder or conflict issue: federal record. Study type: regulatory record.